Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra, Edmund Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, Scott Killian, J. Scott McClellan, Nate Fernhoff, Robert Lowsky

Blood (2025) 146 (Supplement 1): 932.

https://doi.org/10.1182/blood-2025-932

Published: 2025

Journal Articles

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Tuan Phan, Evandro Bezerra, Hannah Choe, Nathan Denlinger, Marcos de Lima, Sam Penza, Gabriela Sanchez-Petitto, Jeremy Sen, Polina Shindiapina, Justin Tossey, Sumithira Vasu, Sarah Wall, Jiasheng Wang

Blood (2025) 146 (Supplement 1): 4217.

https://doi.org/10.1182/blood-2025-4217

Published: 2025

Journal Articles

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Blood (2025) 146 (Supplement 1): 2385.

https://doi.org/10.1182/blood-2025-2385

Published: 2025

Journal Articles

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

Leyla Shune, Anthony Stein, Damiano Rondelli, Laurie Davis, Shalini Shenoy, Britnie Thomas, Emily Andersen, Elizabeth Jordan, Karim Moftah, Zhenyi Xue, Hannah Choe

Blood (2025) 146 (Supplement 1): 6008.

https://doi.org/10.1182/blood-2025-6008

Published: 2025

Journal Articles

BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd

Blood (2025) 146 (Supplement 1): 5859.

https://doi.org/10.1182/blood-2025-5859

Published: 2025

Journal Articles

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Sayan Mullick Chowdhury, Qiuhong Zhao, Sarah Wall, Hannah Choe, Sam Penza, Evandro Bezerra, Lynn Odonnell, Merle Kolk, Michael Daunov, Ashley Krull, Marcos de Lima, Leland Metheny, Sumithira Vasu

Blood (2025) 146 (Supplement 1): 7790.

https://doi.org/10.1182/blood-2025-7790

Published: 2025

Journal Articles

Anti-inflammatory drug pegtarazimod (RLS-0071) demonstrates clinical improvement in lower gastrointestinal acute graft-versus-host disease (aGvHD) and target engagement of key inflammatory marker myeloperoxidase (MPO)

Robert Zeiser, Hannah Choe, José Antonio Pérez-Simón, Kenji Cunnion, Monzr M. Al Malki

Blood (2025) 146 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2025-2462

Published: 2025

Journal Articles

Grade I acute graft-vs-host disease: Treat or not?

Blood (2025) 146 (Supplement 1): 2461.

https://doi.org/10.1182/blood-2025-2461

Published: 2025

Journal Articles

Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib

Henry Castellani, Jean Caputo, Qiuhong Zhao, Justin Tossey, Marcos de Lima, Sumithira Vasu, Sarah Wall, Gabriela Sanchez-Petitto, Evandro Bezerra, Hannah Choe

Blood (2025) 146 (Supplement 1): 4233.

https://doi.org/10.1182/blood-2025-4233

Published: 2025

Journal Articles

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

Jiasheng Wang, Tuan Phan, Pedro Silberman, Evandro Bezerra, Jonathan Brammer, Hannah Choe, Nathan Denlinger, Marcos de Lima, Sam Penza, Gabriela Sanchez-Petitto, Polina Shindiapina, Sumithira Vasu, Sarah Wall, Reza Averly, Xia Ning, Bradley Blaser

Blood (2025) 146 (Supplement 1): 4352.

https://doi.org/10.1182/blood-2025-4352

Published: 2025

Journal Articles

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Zachariah DeFilipp, Hannah Choe, Yvonne A. Efebera, Ayman Saad, Shatha Farhan, Lazaros Lekakis, Jean A. Yared, Gary Schiller, Markus Y. Mapara, Amer Assal, Ted Gooley, Jack D. Bui, Dana Lee, Hayley Lane, Yi-Bin Chen

Blood (2025) 146 (17): 2037–2046.

https://doi.org/10.1182/blood.2025029584

Published: 2025

Includes: Supplemental data

Journal Articles

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 4507.

https://doi.org/10.1182/blood-2024-206559

Published: 2024

Journal Articles

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Blood (2024) 144 (Supplement 1): 384.

https://doi.org/10.1182/blood-2024-203344

Published: 2024

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Manan Shah, Rathan Kumar, Lotus Neidemire-Colley, Mandi Zhu, Nicholas Yuhasz, Malith Karunasiri, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 4906.

https://doi.org/10.1182/blood-2024-199900

Published: 2024

Journal Articles

Real-World Clinical Outcomes of Severe, Treatment-Refractory Chronic Gvhd Patients Treated with Axatilimab Combination Therapies

Ayush V Peddireddi, Jean Caputo, Sarah A. Wall, Sumithira Vasu, Sam Penza, Kevin Ho, Vincent Esguerra, Benjamin Kaffenberger, Hannah Choe

Blood (2024) 144 (Supplement 1): 7362.

https://doi.org/10.1182/blood-2024-206425

Published: 2024

Journal Articles

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Manan Shah, Mandi Zhu, Rathan Kumar, Malith Karunasiri, Lotus Neidemire-Colley, Nicholas Yuhasz, Elizabeth Miller, Marcos de Lima, Parvathi Ranganathan, Hannah Choe

Blood (2024) 144 (Supplement 1): 7336.

https://doi.org/10.1182/blood-2024-201863

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Blood (2024) 144 (Supplement 1): 3446.

https://doi.org/10.1182/blood-2024-198872

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell (CD19.CART) therapy for B-cell lymphomas: Final phase I trial results

Safety analysis of axatilimab in patients with chronic graft-versus-host disease in an expanded access program

BET inhibition targets pathogenic interstitial macrophages to limit antibody mediated fibrosis in bronchiolitis obliterans chronic gvhd

CD34 selected stem cell boost provides robust outcomes in patients with poor graft function

Anti-inflammatory drug pegtarazimod (RLS-0071) demonstrates clinical improvement in lower gastrointestinal acute graft-versus-host disease (aGvHD) and target engagement of key inflammatory marker myeloperoxidase (MPO)

Grade I acute graft-vs-host disease: Treat or not?

Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib

Locally deployed large language models for automated data curation in allogeneic hematopoietic stem cell transplantation

RGI-2001 for the prophylaxis of acute graft-versus-host disease after allogeneic HCT

Steroid Prophylaxis in Patients Receiving CAR T-Cell Therapy for Relapsed and Refractory Non-Hodgkin Lymphoma

Refinement of Day 28 Treatment Response Criteria for Acute GVHD: A Collaboration Study of the JSTCT and MAGIC

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Bromodomain/Extra-Terminal Inhibition (BETi) and Ruxolitinib: Immune Profiling Insights from Human Samples in Acute Gvhd

Real-World Clinical Outcomes of Severe, Treatment-Refractory Chronic Gvhd Patients Treated with Axatilimab Combination Therapies

Comparing Immune Reconstitution in Post-Transplant Cy Myeloablative Vs Reduced Intensity Transplants: Notable Trends in Monocyte Population

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Association between Post-CART Terminal Complement Complex Levels and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only